NOVAVAX INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. FORM 10-K SUMMARY
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NOVAVAX, INC. | |
| By: | /s/ John C. Jacobs |
| John C. Jacobs | |
| President and Chief Executive Officer |
Date: February 26, 2026
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
| Name | Title | Date |
|---|---|---|
| /s/ John C. Jacobs | President and Chief Executive Officer and Director (Principal Executive Officer) | February 26, 2026 |
| John C. Jacobs | ||
| /s/ James P. Kelly | Executive Vice President, Chief Financial Officer, and Treasurer (Principal Financial and Accounting Officer) | February 26, 2026 |
| James P. Kelly | ||
| /s/ Margaret G. McGlynn | Chairman of the Board of Directors | February 26, 2026 |
| Margaret G. McGlynn | ||
| /s/ Gregg H. Alton | Director | February 26, 2026 |
| Gregg H. Alton | ||
| /s/ Richard H. Douglas | Director | February 26, 2026 |
| Richard H. Douglas | ||
| /s/ Rachel K. King | Director | February 26, 2026 |
| Rachel K. King | ||
| /s/ Margaret G. McGlynn | Director | February 26, 2026 |
| Margaret G. McGlynn | ||
| /s/ David M. Mott | Director | February 26, 2026 |
| David M. Mott | ||
| /s/ Charles W. Newton | Director | February 26, 2026 |
| Charles W. Newton | ||
| /s/ Richard J. Rodgers | Director | February 26, 2026 |
| Richard J. Rodgers | ||
| /s/ John W. Shiver | Director | February 26, 2026 |
| John W. Shiver | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Years ended December 31, 2025, 2024, and 2023
Contents
| Reports of Independent Registered Public Accounting Firm (PCAOB ID:42) | F- 2 |
|---|---|
| Consolidated Statements of Operations and Statements of Comprehensive Income (Loss) for the years ended December 31, 2025, 2024, and 2023 | F- 5 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | F- 6 |
| Consolidated Statements of Changes in Stockholders’ Deficit for the years ended December 31, 2025, 2024, and 2023 | F- 7 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024, and 2023 | F- 8 |
| Notes to Consolidated Financial Statements | F- 9 |
F- 1
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.